title: [Therapeutic Efficacy of Multigly-Cosidorum Tripterygium Combined with rhIL-11 for Immune Thrombocytopenia].
abstract: OBJECTIVE
  To study the therapeutic efficacy of multigly-cosidorum Tripterygium combined with rhIL-11 for treating patients with immune thrombocytopenia (ITP).
  
  
  METHODS
  A total of 75 patients with ITP were divided into 2 group: experimental group and control group. The experimental group included 40 patients who had been treated with multigly-cosidorum Tripterygium combined with rhIL-11. Multigly-cosidorum Tripterygium was given at a dose of 1mg/kg·d for 2 months and rhIL-11 was injected at a dose of 16,000,000 units per day. Control group included 35 patients who had been treated with prednisone at a dose of 1 mg/kg·d. Platelet counts were performed every day before platelet counts >30 × 10⁹/L. Peripheral blood T cells were collected before and after treated for 2 months. The ratios of CD4⁺, CD8⁺ T cells in peripheral blood T cells were analyzed by flow cytometry.
  
  
  RESULTS
  Totally effective rate in experimental group was 77.5%. Totally effective rate in control group was 82.9%. Totally effective rate showed no statistical difference between these two groups (P > 0.05). The average time of platelet count 30 × 10⁹/L in experimental and control groups were 13.06 ± 6.10 days and 9.76 ± 5.71 days respectively; in experimental group, the ratio of CD4⁺ T cells in peripheral blood was 21.03% before treatment, then rised to 34.49% after treatment for 2 months (P < 0.01); The ratio of CD8⁺ T cells in peripheral blood was 26.35% before treatment, then decreased to 20.18% (P < 0.01). In control group, the ratio of CD4⁺ T cells was 22.30% before treatment, then rised to 25.11% after treatment for 2 months (P < 0.05); The ratio of CD8⁺ T cells in peripheral blood was 27.24% before treatment, then decreased to 21.35% (P < 0.01).
  
  
  CONCLUSIONS
  Multigly-cosidorum tripterygium can correct disorder of T lymphocytes, the combination of multigly-cosidorum triptergium and rhIL-11 can accelerate therapeutic efficacy for treating ITP and with less adverse reaction, so this combination may be effective and safe for treating patients with ITP.
authors.affiliation: Department of Hemotology, Affiliated Hospital of Jiangsu University, Zhenjiang 212001, Jiangsu Province, China.
authors.forename: Xian-Qiu
authors.initials: XQ
authors.lastname: Yu
authors.affiliation: Department of Hemotology, Affiliated Hospital of Jiangsu University, Zhenjiang 212001, Jiangsu Province, China.
authors.forename: Hong-Mei
authors.initials: HM
authors.lastname: Chen
authors.affiliation: ICU of Xiamen Changgeng Hospital, Xiamen 361000, Fujian Province, China.
authors.forename: Jin-Hua
authors.initials: JH
authors.lastname: Sun
authors.affiliation: Department of Hemotology, Affiliated Hospital of Jiangsu University, Zhenjiang 212001, Jiangsu Province, China.
authors.forename: Ming
authors.initials: M
authors.lastname: Luo
authors.affiliation: Department of Hemotology, Affiliated Hospital of Jiangsu University, Zhenjiang 212001, Jiangsu Province, China. E-mail: healthyxq@126.com.
authors.forename: Yi-Long
authors.initials: YL
authors.lastname: Lu
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D006801:Humans; D017370:Interleukin-11 / Q000627:therapeutic use*; D010976:Platelet Count; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000188:drug therapy*; D011994:Recombinant Proteins / Q000627:therapeutic use; D013601:T-Lymphocytes; D029757:Tripterygium / Q000737:chemistry*
chemical_list: D000970:Antineoplastic Agents; D004365:Drugs, Chinese Herbal; D017370:Interleukin-11; D011994:Recombinant Proteins; C105308:oprelvekin